Cargando…
SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
Diabetic kidney disease (DKD) is the most common cause of end stage renal disease. The comprehensive management of DKD depends on combined target-therapies for hyperglycemia, hypertension, albuminuria, and hyperlipaemia, etc. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, the most recently deve...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5434580/ https://www.ncbi.nlm.nih.gov/pubmed/28511711 http://dx.doi.org/10.1186/s12933-017-0547-1 |